You can buy or sell PRTO and other stocks, options, ETFs, and crypto commission-free!
Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. Read More The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMar 14
Proteon files for stock offering; shares down 4% after hours
Proteon Therapeutics (NASDAQ:PRTO) has filed a preliminary prospectus for an unspecified stock offering. Shares are down 4% after hours....
Yahoo FinanceMar 13
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31, 2018, and recent business highlights. “We are looking forward to the expected release this month of top-line results from PATENCY-2, our second Phase 3 clinical trial of investigational vonapanitase,” said Timothy Noye...
Simply Wall StMar 8
How Does Investing In Proteon Therapeutics, Inc. (NASDAQ:PRTO) Impact The Volatility Of Your Portfolio?
Anyone researching Proteon Therapeutics, Inc. (NASDAQ:PRTO) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The second type is the broader market volatility, which you canno...
-$0.26 per share
-$0.27 per share